This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. The current DSI venture -First International Congress of SAARCUM -was governed by multi-regional and multi-specialty approach, the bare essentials to tackle the epidemic of antifungal therapeutic failures (AFTF) overwhelming South Asia and spreading across the globe. The scientific programme was delivered by including Chairpersons, 35 Speakers [ Figure 1 ], 2 quiz masters, and presenters of 6 shortlisted Award papers and 5 E-Posters. International faculties included representatives from the National Societies of Dermatology of Nepal, Sri Lanka, and Bangladesh. Experienced faculties from different specialties contributed to multiple facets of clinical mycology.
The nuisance of widespread failure of antifungal pharmacotherapy in the treatment of superficial cutaneous mycosis, especially dermatophytic infections has become daunting for practitioners across South Asia. Although multiple sporadic attempts at the regional/national level have been conducted to find a solution to this menace in India, the need of the hour was the formation of a dedicated international alliance that eventuated in the creation of the South Asian Alliance against Recalcitrant CUtaneous Mycosis (SAARCUM), coordinated by Dr Sidharth Sonthalia (Dermatologist) from India, and involving participation from South Asian countries including Nepal, Sri Lanka, Bangladesh, Thailand, and Singapore. The second essential aspect of such an alliance i.e. involvement of medical specialists other than dermatology was also ensured. Today, SAARCUM is a conglomeration of dermatologists, microbiologists, epidemiologists, senior scientists involved in mycology research, internists, pediatricians, and psychiatrists.
DERMASOURCE
INDIA (DSI), a well-known venture of dermatologists and management experts, credited with holding the first ever National Dermoscopy Conclave of India in 2015 followed by focused conclaves on niche areas like polycystic ovary syndrome (PCOS), platelet-rich plasma (PRP), psychodermatology, hair transplantation amongst others, and International Organizing partner for various Congresses held by different National Dermatology Associations/Societies (Nepal, University of Cairo, Spring Continental Congress of Dermatology, Tehran, and Sri Lankan College of Dermatologists -SLCD) organized the First International Congress of SAARCUM on 17 th November, 2018 at Medanta -The Medicity, Gurugram, India [www.dermasourceindia.com].
The current DSI venture -First International Congress of SAARCUM -was governed by multi-regional and multi-specialty approach, the bare essentials to tackle the epidemic of antifungal therapeutic failures (AFTF) overwhelming South Asia and spreading across the globe. The scientific programme was delivered by including Chairpersons, 35 Speakers [ Figure 1 ], 2 quiz masters, and presenters of 6 shortlisted Award papers and 5 E-Posters. International faculties included representatives from the National Societies of Dermatology of Nepal, Sri Lanka, and Bangladesh. Experienced faculties from different specialties contributed to multiple facets of clinical mycology.
The conference was attended by 162 delegates from across the length and breadth of India, and neighboring countries including Nepal, Bhutan, Bangladesh, and Sri Lanka. While the majority of delegates were dermatologists, a substantial number hailed from internal medicine and pediatrics, a positive trend since inclusion of all primary stake-holders is imperative to win this battle against mycoses.
The scientific proceedings started with the Award Paper session. Out of 17 abstracts received, the 6 most meritorious papers pertaining to research in cutaneous mycology were presented by the residents [ Figure  2 ]. The DSI-SAARCUM inter-collegiate postgraduate quiz -prelims were conducted and of the 11 participating teams, 4 teams were shortlisted for the finals.
To stimulate and foster the learning potential of the delegates, DSI always holds a Pre-and Post-Test Analysis for all delegates. It included 30 questions (MCQs, Pictorial, Dermoscopic) directly related to cutaneous mycology, which were contributed by the Congress Speakers, on the premise that careful tending to their lectures would give away the answers one-by-one.
The learning points from different lectures, dialogue sessions, and workshops are presented in this paper. • Superficial mycoses affect 20-25% of the world's population • There has been an alarming increase in the number of "recalcitrant/resistant" superficial mycoses, from India, South Asia, and globally in the last few years • The cases constitute the "tip of the iceberg" and there lies a substantial paucity of evidence • The environment, host, and agent factors are responsible for the changing landscape • Reduced bioavailability when co-administration with antacid medications • Dependent on intake post meals and the effect of aerated drinks. Recent studies have shown that taking itraconazole with a cola drink does not enhance its bioavailability • Serum levels affected by drug brand and pellet size.
• The sub-inhibitory concentrations of itraconazole achieved in patient's serum significantly increase the likelihood of secondary azole resistance by selection pressure, rendering them resistant to any further course of itraconazole, since azoles being fungistatic allow persistence of organisms • The selection pressure-induced secondary resistance resulting from oral itraconazole is also seen to perpetuate pan-triazole and partial terbinafine and amorolfine resistance. Ciclopirox olamine is the only drug without a propensity to develop resistance • Itraconazole-resistant strains show high levels of cross-resistance to multiple triazoles including voriconazole and posaconazole, and often to six triazole fungicides used extensively in agriculture, qualifying for multi-triazole resistance (MTR) • Azole-resistant fungi are more virulent because of the differences in cell wall composition, increased filamentation and adherence, and enhanced biofilm formation. Once acquired, resistance is maintained even in the absence of drug
• Primary azole resistance due to their widespread use as agricultural fungicides, further adds to the azole menace. As per the statistics available from the website of the Indian Ministry of Agriculture, in the 4-year period from 2012 to 2016, there was an estimated 29.5% decrease and 34.2% increase in the consumption of insecticides and fungicides, respectively • The spreading azole resistance in superficial fungal infections resulting in selection of a population of mutants that do not respond to any drug is likely to have graver ramifications in invasive dermatophytosis in immunocompromised individuals • Resistance to terbinafine on the other hand, acquired through a rare mechanism, is infrequent, shows restoration of susceptibility after drug removal and has not been reported to confer cross-resistance to other antifungal agents • The dosing of terbinafine should be as per body weight, 6 mg/kg/day and it should be given for a duration of 8 (minimum) to 12 weeks (preferred), with monitoring of liver function tests, taking into consideration the dermatophytic involvement of vellus hair.
Dr Saurabh Shah, Senior Consultant Dermatologist, Bhatia
Hospital, Mumbai talked on the "Generalists -Specialists Divide," an important issue in the problem of antifungal therapeutic failures.
• The core problem behind misuse of topical corticosteroids and injudicious use of antifungals is the deficient training of primary care physicians • The need of the hour is to draft guidelines on the basis of evidence rather than expert consensus and to extend their benefit to the health-care personnel who treat much larger patient populations than those treated by dermatologists, through continuing medical education and training workshops for general practitioners • Improvement in the standards of dermatology training in medical schools at undergraduate and postgraduate levels • Intensification of efforts to reduce inappropriate prescription of corticosteroids; and their enforcement at the ground level. With an availability of over 175 brands of itraconazole, there is a heightened awareness regarding its varying efficacy. Similar concerns also exist with topical antifungal agents. According to the World Health Organization (WHO) report, 10% of the topical formulations available in India are of sub-standard quality.
• WHO-cGMP (World Health Organization -companies Good Manufacturing Process) accreditation status of the manufacturing unit is essential to ensure efficacy and stability of a topical product.
• Quality control procedures include:
• Real-time stability testing: Done at -25 ± 2°C/60 ± 5°C relative humidity. To evaluate the stability of the drug under normal storage conditions expected in the intended market, for selection of adequate formulation and determination of shelf life. Requires a periodic testing of over at least 24 months • Accelerated time study: Done at -40 ± 2°C/75 ± 5°C relative humidity. To assess stability at extremes of physical conditions and to evaluate the impact of short-term excursions outside the label storage conditions e.g., during transport. The following issues were addressed:
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• The problem of recalcitrant cutaneous mycoses is a major epidemic across all South Asian countries • The use of oral itraconazole has indeed made the situation worse • The countries share a lack of public awareness and counseling the patients about general measures is of paramount importance • Terbinafine continues to give good results.
Non-availability of ciclopirox olamine is an issue in some of the South Asian countries
• Experience with alternative treatments with natural products, phototherapy, and lasers is mostly lacking in all countries • There is a need for multicentric studies to determine anti-fungal susceptibility patterns across South Asia. SAARCUM must be formalized as a registered international forum for further such discussions. Dr Sangeeta Verma, Senior Consultant Dermatologist, Gurugram presented a talk on the utility of "Light therapy: PDT, UVR and more."
• Innovative approach to treatment in cases of drug resistance, poor candidates for oral antifungal therapy, and patients non-responsive to multiple topical antimycotics • Photodynamic Therapy -Systemic/topical photosensitizers (chlorines, porphyrins, phenothiazines, phthalocyanins) are given along with illumination (optimal wavelength -410 nm) of a target lesion. Acts by oxidative photodamage at the site. Light penetration in blue region is 1.5 mm and red region is 3 mm. Although it is available at handful of centers in India, they are being used by oncologists • Ultraviolet Therapy -UVB light shows maximum efficacy in inhibition of both T. rubrum and T. mentagrophytes. Studies show good efficacy in cases of pityriasis versicolor and seborrheic dermatitis. Acts by releasing a variety of pro-inflammatory and immunosuppressive cytokines and anti-microbial peptides from keratinocytes and T-cells. Vitamin D produced during phototherapy may also be responsible • Light-emitting diode (LED) therapy -Exposure at 280 nm, with a fluence of 0.5 J/cm 2 showed inhibitory effect on T rubrum, indicating its potential role as a low-cost in home treatment or disinfection method • Sun Therapy -Used for interdigital tinea pedis not responding to topical antifungals. Boosted solar therapy given by using simple convex hand lens (focal length 20 cm, diameter 9.5 cm), held at 17 cm to focus the solar radiation on the infected area for 30-50 s.
Complete clinical cure was achieved by 17 th day and no relapse was observed at 4 months follow up. • Potassium iodide (broad-spectrum antiseptic and disinfectant activity).
• The nail folds and cuticles were occluded with vaseline and a uniform coat of combination peel was applied over the infected toe nails, followed by a second coat 20 min later. After 40 min, the peel was washed off with distilled water followed by application of 8% ciclopirox olamine (CPO) or amorolfine nail lacquer • Peel sessions, given weekly for 4 weeks and fortnightly for the next 4-6 months with daily self-application of CPO lacquer by the patient at night have shown clinical improvement at 4 weeks and complete mycological cure by 6 months. The first report of cure of toe nail onychomycosis with this protocol has been recently published. The key highlights of the session were:
• In tinea patients with multiple comorbidities, terbinafine and fluconazole are preferred systemic antifungal agents. Itraconazole is the only affordable treatment option for invasive fungal infections and should not be used for superficial mycoses • Baseline liver function tests repeated after 6 weeks of therapy are recommended for systemic antifungal treatment. Preferred oral treatment for a patient of erythrodermic tinea with deranged liver functions -terbinafine with hepatoprotective agents such as silymarin 140 mg BD and/or S-adenosylmethionine (SAM) 400 mg BD, with close monitoring of liver functions • Terbinafine oral granules are US-FDA approved for use in Tinea capitis in children aged ≥4 years and griseofulvin for >2 years. Due to non-availability of terbinafine oral granules in South Asia, the 250 mg tablet has to be divided or 125 mg dispersible tablet can be used • Dermoscopy is a useful method for dermatophytic diagnosis and avoids scraping related anxiety in children • Topical antifungals are preferred for treatment of fungal infections in pregnant women. Ciclopirox olamine cream obviates the need for topical steroids due to its potent anti-inflammatory activity • Oral terbinafine is pregnancy category B and can be used in extensive cases, especially after 1 st trimester • Dermatologists often tend to underestimate the psychological disturbances (depression, anxiety) present in patients with complicated tinea. Psychological well-being must be an important consideration in patients with chronic and recalcitrant dermatophytoses
• Patient Health Questionnaire-9 (PHQ-9) score, a 2-min OPD evaluation can be easily used in every skin clinic to assess patient's reaction to the problem and the need for psychiatry consult • Escitalopram and desvenlafaxine are the newer anti-depressant medications that can be safely used with lesser risk of side-effects and drug interactions and a rapid response within 1-2 weeks. Figure 3 gives a glimpse into the scientific proceedings of the Congress.
The Congress concluded with the Quiz Finale in which the four Quiz teams that were shortlisted after the Prelims fought it out for the crown [ Figure 4 ].
Future Directives from the First International Congress of SAARCUM
• Formalization of DSI-SAARCUM into a registered organization with a set of goals and deadlines for regional cooperation • Regional multicentric in vivo and in vitro trials to be 
